TARRYTOWN, N.Y., Oct. 10, 2019 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced
that it will report its third quarter 2019 financial and operating
results on Tuesday, November 5, 2019,
before the U.S. financial markets open. The Company will host a
conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
To access this call, dial
(800) 708-4540 (U.S.) or (847) 619-6397 (International). A link to
the webcast may be accessed from the 'Investors and Media' page of
Regeneron's website at http://investor.regeneron.com/events.cfm. A
replay of the conference call and webcast will be archived on the
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that
invents life-transforming medicines for people with serious
diseases. Founded and led for 30 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to seven FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, infectious diseases,
pain and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune® which produces
optimized fully-human antibodies, and ambitious research
initiatives such as the Regeneron Genetics Center, which is
conducting one of the largest genetics sequencing efforts in the
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
SOURCE Regeneron Pharmaceuticals, Inc.